Cefminox

As a representative cephamycin antibacterial drug, cefminox exerts a dual bactericidal effect by inhibiting the synthesis of bacterial cell walls and binding to bacterial peptidoglycan. It exhibits broad-spectrum antibacterial activity against Gram-negative bacteria and anaerobes, with particularly prominent antibacterial efficacy against drug-resistant strains producing β-lactamase. Clinically, it is mainly used for the treatment of severe infections such as respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections and sepsis caused by susceptible bacteria. It is applicable to adult and pediatric patients with various moderate to severe bacterial infections, and is one of the important options for clinical anti-infective treatment.

The current global market size of cefminox exceeds 600 million US dollars, and the domestic market size is approximately 2.3 billion RMB, maintaining a steady growth of 3%-5% in recent years. From the perspective of competitive landscape, the domestic preparation market has formed a pattern of co-supply by originator drugs and generic drugs. At present, cefminox preparations from nearly 20 enterprises have passed the generic drug consistency evaluation, and multiple products have been included in the national centralized procurement catalogue. The winning bid price has dropped by more than 60% compared with that before the centralized procurement, and clinical accessibility has been greatly improved. The upstream supply of active pharmaceutical ingredients (APIs) is dominated by domestic enterprises, with sufficient overall production capacity.

The originator enterprise of cefminox is Meiji Seika Pharma Co., Ltd. of Japan, with the original brand name "Meicelin". Its core compound patent expired in 2007, and all domestic preparation patents have also expired. The main dosage form approved for the originator product is cefminox sodium for injection, with conventional specifications of 0.5g and 1.0g. The originator product has been included in the *Catalogue of Chemical Reference Preparations* issued by the National Medical Products Administration. According to the domestic API registration platform, 12 enterprises have obtained A-status registration numbers for their cefminox APIs, which can be used for associated preparation declaration or marketing. All domestically approved cefminox preparations are injections, which have covered the clinical needs of medical institutions at all levels. (Data as of September 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of cefminox impurity reference standards, covering all types of impurities involved in the synthesis process and degradation process. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can meet the reference substance needs of the whole process of API R&D, quality research and registration declaration.